Form 4 for DXCM Dexcom
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-08 · accession 0001093557-24-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-11 | 2024-03-08 | DXCM | Brown Michael Jon | EVP CLO | A - Grant | $0.00 | +21.7K | 80.1K | +37% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | A | A | 21,711 | $0.00 | 80,105 | D | — | — | (F1) Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. (F2) Included in this number are 60,303 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 24,080 of which were granted on March 8, 2022 and shall vest through March 8, 2026. |